37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: Overall survival (OS) by MMR status and molecular subgroups

作者：M.A. Powell, Annika Auranen, Lyndsay J. Willmott, L. Gilbert, D. Black, David Cibula, S. Sharma, G. Valabrega, Lisa Michelle Landrum, L.C. Hanker, Ashley R. Stuckey, Ingrid A Boere, M. Gold, Mark S. Shahin, Bhavana Pothuri, B.M. Slomovitz, M. Grimshaw, S. Stevens, Robert Louis Coleman, Mansoor Raza Mirza · 发表于：ESMO Open · 年份：2024 · DOI：10.1016/j.esmoop.2024.103537 · 被引用次数：5 · 研究领域：Endometrial and Cervical Cancer Treatments、Ovarian cancer diagnosis and treatment、Sarcoma Diagnosis and Treatment

At interim analysis (IA) 1 of Part 1 of the RUBY trial (NCT03981796), statistically significant benefit in PFS was observed with dostarlimab+carboplatin-paclitaxel (D+CP) vs placebo (PBO)+CP in the overall and mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) populations of pts with pA/rEC. Here we report OS from IA2.